Gaps in Biosimilar Assessment Reports Pique Investigator Interest

August 31, 2020

According to a recent evaluation of health technology assessments (HTAs) for biosimilars, researchers found the majority of HTAs lack systematic reviews of existing literature, cost analyses, and quality of evidence appraisals. In conclusion, the authors state that minimum methodological criteria for the development of HTAs for biosimilars is essential in supporting public understanding of these agents and enabling clinicians to “make more informed decisions about adopting biosimilars.” Read the full study here.

Share This Story!